

---

# Lessons learnt from integrating grEPI into WHO's mpox dashboard

*Steve Kerr*

11 June 2025

# Background: WHO Mpox Dashboard

- **Launched in Summer 2022** to enable **transparent** and **timely** sharing of outbreak data amid rising global cases
- Built using **R** and **Shiny**
- **Key sections included:**
  - Global trends
  - Case demographics
  - Transmission dynamics
  - Downloadable summary data
- Added a section on **mpox epidemiological parameters** sourced from scientific literature


### Contents

- Key figures
- 1. Overview
- 2. Summary of MPXV clades
- 3. Situation in Africa
- 4. Situation in the DRC
- 5. Global Situation
- 6. Epidemiological parameters
- 7. Download data
- 8. Additional information

## Global Mpox Trends

AUTHOR  
World Health Organization

PUBLISHED  
June 2, 2025



### Key figures

This report provides a comprehensive summary of data from the global mpox surveillance started by WHO in 2022, and strengthened during the ongoing public health emergency of international concern (PHEIC). For information on specific topics:

Topic	Relevant sections
Global distribution of clade Ib MPXV	<a href="#">Section 2.2</a>
Clade II, Ia, and Ib MPXV in Africa	<a href="#">Section 3</a>
Clade Ia and Ib MPXV in the Democratic Republic of the Congo	<a href="#">Section 4</a>
Global epidemiology (largely clade IIb MPXV)	<a href="#">Section 5</a>

[Weekly trends in Africa](#) [Totals for key countries](#) [Totals for Africa](#) [Global totals](#)

[Clades detected globally](#)

For further information on the epidemiological situation in Africa, see [Section 3](#)

# Mpox Epi Parameters

- Public Health Agency of Canada (PHAC) developed a repository of mpox-related literature
- Integrated data from **multiple sources**, including PubMed, Scopus, Europe PMC, and others
- Extracted key information:** metadata, epi parameter type, reported values, distributions, and uncertainty bounds
- Regularly updated** to ensure comprehensive and timely coverage
- Used to develop the **initial version** of the mpox epi parameters section



Monkeypox Literature List - CURRENTLY UPDATED WEEKLY ON TUESDAYS STARTING OCTOBER 2024 (see methods for history of update cycle frequency)									
Contact Lisa Waddell @ NML, PHAC for more information lisa.waddell@phac-aspc.gc.ca									
Refid	Bibliography	Author	Abstract	Primary?	Clade 1	Included in Feb 26 Clade 1 LEP (yes)	Comments for clade 1		
Search Date									
5/31/2022	2 A Novel International Monkeypox Outbreak ( 2 ) Ann Intern Med . Adajia, A., Inglesby, T. 2022/05/24 (2022): #naaes#--> 10.7326/m22-1581 : #URL#	Adajia, A., Inglesby, T.		NOT Primary					
5/31/2022	3 Clinical features and management of human monkeypox: a retrospective observational study in the UK ( 3 ) Lancet Infect Dis . Adler, H., Gould, S., Wong, W., Houlihan, C. F., Osborne, J. C., Rammler, T., Readsworth, M. B., Duncan, Cohen, J.	Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., Osborne, J. C., Rammler, T., Readsworth, M. B., Duncan, Cohen, J.	BACKGROUND: Cases of human monkeypox are rarely seen outside of west and central Africa. There Rapid emergence of hundreds of cases around the world alarms public health officials and scientists. A case of monkeypox was diagnosed in a returning traveler from Nieria to Marvland. USA.	Yes - Primary					
5/31/2022	20 Imported Monkeypox from International Traveler, Maryland, USA, 2021 ( 23 ) Emerg Infect Dis . Costello, V., Sowash, M., Gaur, A., Cardis, M., Pasieka, H., Wortmann, G., Ramdeen, S.	Costello, V., Sowash, M., Gaur, A., Cardis, M., Pasieka, H., Wortmann, G., Ramdeen, S.	A case of monkeypox was diagnosed in a returning traveler from Nieria to Marvland. USA.	Yes - Primary					
5/31/2022	30 Investigating the monkeypox outbreak ( 30 ) Bmj . Dye, C., Kraemer, M. U. G. 377,2022/05/27 (2022): o1314--> 10.1136/bmi.o1314 :	Dye, C., Kraemer, M. U. G.		NOT Primary					
5/31/2022	36 In Silico Identification of Non-cross-reactive Epitopes for Monkeypox Cell Surface-Binding Protein ( 36 ) Research Square nreub . Gao, Andrew, Gao, Sarah.	Gao, Andrew, Gao, Sarah	Smallpox, a disease caused by the Variola virus, was eradicated after global vaccination efforts. Recentlv.	Yes - Primary					
5/31/2022	39 Daily briefing: Why scientists are worried about monkeypox ( 39 ) Nature . Graham, F. 2022/05/24 (2022): #naaes#--> 10.1038/d41586-022-01455-v :	Graham, F.		NOT Primary					
5/31/2022	42 What to Know About Monkeypox ( 42 ) Jama . Harris, E. 2022/05/28 (2022): #pages#--> 10.1001/jama.2022.9499 : #URL#	Harris, E.		NOT Primary					
5/31/2022	55 Monkeypox goes global: why scientists are on alert ( 55 ) Nature . Kozlov, M. 2022/05/21 (2022): #naaes#--> 10.1038/d41586-022-01421-8 : #URL#	Kozlov, M.		NOT Primary					
5/31/2022	56 Monkeypox outbreaks: 4 key questions researchers have ( 56 ) Nature . Kozlov, M. 2022/05/28 (2022): #naaes#--> 10.1038/d41586-022-01493-6 : #URL#	Kozlov, M.		NOT Primary					
5/31/2022	61 Seven monkeypox cases are confirmed in England ( 61 ) Bmj . Mahase, E. 377,2022/05/18 (2022): o1239--> 10.1136/bmi.o1239 : #URL#	Mahase, E.		NOT Primary					
5/31/2022	62 Monkeypox: What do we know about the outbreaks in Europe and North America? ( 62 ) Bmj . Mahase, E. 377,2022/05/21 (2022): o1274--> 10.1136/bmi.o1274 :	Mahase, E.		NOT Primary					
5/31/2022	63 Exportation of Monkeypox Virus From the African Continent ( 63 ) J Infect Dis . Mauldin, M. R., McCollum, A. M., Nakazawa, Y. J., Mandra, A., Whitehouse, F. R., Davidson, W., Zhao, H., Gao, J. I. Y., Moore, M., Zahra, F.	Mauldin, M. R., McCollum, A. M., Nakazawa, Y. J., Mandra, A., Whitehouse, F. R., Davidson, W., Zhao, H., Gao, J. I. Y., Moore, M., Zahra, F.	BACKGROUND: The largest West African monkeypox outbreak began September 2017, in Nigeria. Four Monkeypox virus was first isolated and identified in 1958 when monkev shioed from Singapore to	Yes - Primary	Yes - Clade I				
5/31/2022	65 Monkeypox ( 65 ) StatPearls . Moore, M., Zahra, F. #volume# (2022): #pages#--> #doi# ; #URL#	Moore, M., Zahra, F.		NOT Primary					
5/31/2022	68 Waking up to monkeypox ( 68 ) Bmj . Nakoune, E., Olliaro, P. 377,2022/05/26 (2022): o1321--> 10.1136/bmi.o1321 : #URL#	Nakoune, E., Olliaro, P.		NOT Primary					
5/31/2022	72 Preliminary structural proteome of the monkeypox virus causing a multi-country outbreak in May 2022 ( 72 ) Research Square nreub . Parigger, Lena.	Parigger, Lena, Krassnigg, Andreas, Grabuschnig, Stefan, et al.	The monkeypox virus (MPX) belongs to the orthopoxvirus genus of the Poxviridae family. is endemic. Monkeypox is a rare, sometimes life-threatening zoonotic infection that occurs in west and central	Yes - Primary					
5/31/2022	78 Monkeypox in a Traveler Returning from Nigeria - Dallas, Texas, July 2021 ( 78 ) Morbidity and Mortality Weekly Report . Rao, A. K., Schulte, J., Chen, T. H., Hughes, C. M., Davidson, W., Neff, J. M., Markarian, M., Delea, K. C., Wada, S., Rudan, I.	Rao, A. K., Schulte, J., Chen, T. H., Hughes, C. M., Davidson, W., Neff, J. M., Markarian, M., Delea, K. C., Wada, S., Rudan, I.		Yes - Primary					
5/31/2022	80 The COVID-19 pandemic: SARS-CoV-2, childhood hepatitis and monkeypox raise five new questions for			NOT Primary					

# 2024-2025 Mpox Outbreak


- **Emergence of new variant (clade Ib)** alongside a surge in cases in DRC and neighboring countries
- **Shifting transmission dynamics** and change in affected populations
- **Dashboard adapted** to focus on highly-affected regions and raise awareness of evolving outbreak trends
- Expanded epi parameter section to:
  - Include **clade information**
  - Specify **study population's country**
  - Incorporate **more recent literature**



UN News  
Global perspective Human stories

AUDIO HUB SUBSCRIBE


## WHO declares mpox virus a public health emergency of international concern



© CDC/Cynthia S. Goldsmith, Russell Regnery | Mpox - formerly monkeypox - is a rare but dangerous infection similar to the now eradicated smallpox virus.


## Mpox: countries affected in Africa

from 1 Jan 2022, as of 25 May 2025



## Trends in global mpox cases by WHO region

data as of 30 Apr 2025



Source: WHO


## Advantages of grEPI

- **Consolidates data** from PHAC, {epiparameter} R package, and other public sources into a single harmonized repository
- **Backed by global partners** across academia and public health sector, with growing community of practice
- **Comprehensive** set of available variables
- Remains under **active development**
- **Updated** with emerging evidence
- **Accessible via RESTful API** delivering structured JSON
- **Documentation for using R to access grEPI** mpox epidemiological parameters available [here](#)



## Additional Mpox parameters to support modelling and analysis

August 2024



### BACKGROUND

The EpiParameter community is a global collaborative working group coordinated by the World Health Organization (WHO), with the aim of establishing an easy-to-use repository of epidemiological parameters accessible by modelers, epidemiologists, subject matter experts and decision makers, to inform mathematical models and other epidemiological analyses and, by extension, public health preparedness and response.

Given the ongoing multi-country Mpox outbreak, a brief extraction of Mpox parameters was undertaken, covering studies already parameterized in the {epiparameter} R package and other publicly available sources. The parameters and data structures provided in this guidance note have been driven and supported by our community partners (see last page of document). This product is one of the key components of the forthcoming Global Repository of Epidemiological Parameters (GREP). The GREP minimum viable product will be made available in early 2025.

Please note that this is an experimental product currently under development.

### AVAILABLE PARAMETERS FOR MPOX ANALYSIS

Parameter label	Definition	Example options (based on what is currently in the repository)
PATHOGEN_FK	Selected parameter of interest	Mpox
PARAM_TYPE_FK	Parameter type	Human delay, Reproduction number (Basic R0)
PARAM_SUBTYPE_FK	Parameter sub-type	Incubation period, generation time, All Reproduction number (Basic R0), serial interval
CLADE	Disease clade	I, IIa, IIb
PARAM_UNIT_FK	Parameter units	Days, No units
PARAM_VAL	Value of the selected parameter	
PARAM_BOUND_LOWER (PARAM_BOUND_UPPER)	Lower/upper bound of the parameter estimate	
PARAM_VALUE TYPE	Value category	Mean, Median
POP_SEX_FK	Gender filter	Male, Both
POP_AGE_MIN (POP_AGE_MAX)	Minimum/Maximum age of the study population	Min: 20, 23, 28; Max: 61, 64, 71
POP_COUNTRY	Country the estimate was produced from	Netherlands, United States, Democratic Republic of Congo, United Kingdom
ARTICLE_LABEL	First author and year of the study	
ARTICLE_TITLE	Title of the study	

# Implementation

- Implemented in **R**, rendered with **Quarto**
- API can be accessed using **standard packages**: `httr`, `jsonlite`, `tidyverse`
- **Key steps**:
  1. Connect to WHO Collaboratory xMart API:  
[https://xmart-api-public-uat.who.int/COLLAB/MPOX\\_PARAMETERS](https://xmart-api-public-uat.who.int/COLLAB/MPOX_PARAMETERS)
  2. Identify and extract relevant fields (e.g., type, subtype, uncertainty bounds, population metadata)
  3. Limit to key parameters: *incubation period, serial interval, generation time*
  4. Infer clade where missing, using genomic surveillance and country/year context
  5. Generate summary tables with `{gt}`, and enable download with `{downloadthis}`
- **Automatically updates** as new evidence is added



## ACCESSING PARAMETERS IN R

To access the mpox parameters, first ensure you have installed the required packages:

```
library(httr)      library(tidyverse)
library(jsonlite)  library(pander)
library(rlist)
```

The core table can then be accessed via the `GET()` function via the public `xmart-api-public-uat.who.int` portal:

```
##--Load tables--##
response1 <- GET("https://xmart-api-public-uat.who.int/COLLAB/MPOX_PARAMETERS")
```

```
#FACT_PARAMETERS
json1 <- content(response1, "text")
FACT_PARAMETERS <- data.frame(fromJSON(json1))

#Tidy column names
FACT_PARAMETERS <- FACT_PARAMETERS %>% rename_with(str_sub, start = 7L)
```

An example of a Mpox parameter extraction query has been provided below.

```
Ex <- subset(FACT_PARAMETERS, PATHOGEN_FK == 'Mpox' &
             PARAM_TYPE_FK == 'Human delay' &
             PARAM_SUBTYPE_FK == 'incubation period' &
             PARAM_UNIT_FK == 'Days')
```

```
Result <- data.frame(Ex$ARTICLE_LABEL, Ex$PARAM_VAL, Ex$PARAM_BOUND_LOWER,
                     Ex$PARAM_BOUND_UPPER, Ex$PARAM_VALUE_TYPE_FK, Ex$POP_COUNTRY)
```

```
colnames(Result) <- c("Article label", "Parameter value", "Lower bound", "Upper bound", "Value type", "Country")
```

Result

## Article label	Parameter value	Lower bound	Upper bound	Value type	Country
## Miura 2022	8.50	6.60	10.90	Mean	Netherlands
## Charniga, 2022	7.60	6.20	9.70	Mean	United States
...					



# Final Product

## Contents

### Key figures

1. Overview
2. Summary of MPXV clades
3. Situation in Africa
4. Situation in the DRC
5. Global Situation
6. Epidemiological parameters
7. Download data
8. Additional information

## 6. Epidemiological parameters

This section of the report highlights studies that estimate key mpox epidemiological parameters—**incubation period**, **serial interval**, and **generation time**—to enhance understanding of the outbreak's dynamics.

The [WHO Collaboratory Epi Parameters Community](#) maintains a user-friendly repository of epidemiological parameters for modelers, epidemiologists, subject matter experts, and decision-makers to support mathematical modeling, public health preparedness, and response.

The presented studies are sourced from:

1. The [epiparameter](#) R package, maintained by [data.org's EpiVerse initiative](#), which includes periodically reviewed literature and accepts user-submitted parameters via a publicly accessible [Google Sheet](#).
2. A literature screening process conducted by the [Public Health Agency of Canada \(PHAC\)](#), established in 2022, with documented inclusion criteria and methodology in the [Methods sheet](#) of their results.

These sources are consolidated in a single repository, accessible via an API (details [here](#)). As this is an experimental product under development, feedback is encouraged via [Collaboratory@who.int](mailto:Collaboratory@who.int).

The tables below summarize the most relevant estimates for **incubation period**, **serial interval**, and **generation time**, derived from these sources.

Parameters Bibliography

Incubation Period Serial Interval Generation Time

Incubation Period											
Reference	Clade	Country	n	Median <sup>1</sup>	Mean <sup>1</sup>	SD <sup>2</sup>	95% CrI / CI <sup>1</sup>	IQR <sup>2</sup>	Range <sup>2</sup>	Distribution	
Marziano, 2024	I	Democratic Republic of the Congo	-	-	9.9	-	-	-	-	Weibull	
Ponce, 2024 <sup>2</sup>	I	Multiple countries	-	-	7.3	-	5 - 10.2	-	-	Gamma	
Ponce, 2024 <sup>2</sup>	II	Multiple countries	-	-	8.9	-	6.6 - 11.7	-	-	Gamma	
Madewell, 2023	IIb <sup>3</sup>	United States	36	-	5.6	-	4.3 - 7.8	-	-	Gamma	
Wang, 2022	I	Congo	-	9.5	-	-	-	8 - 12.2	-	-	
Tarin-Vicente, 2022	II	Spain	144	7.0	-	-	-	5 - 10	1 - 19	-	
Wang, 2022	IIa	United States	-	16.8	-	-	-	11.4 - 23.9	-	-	
Angelo, 2022	IIb <sup>2</sup>	Multiple countries	78	8.0	-	-	-	5 - 11	2 - 40	-	

---

## Lessons Learnt: Integrating grEPI into WHO Mpox Dashboard

- **Learning curve**

- Deriving additional fields (e.g., age ranges, uncertainty bounds)
- Converting data types where necessary

- **Strengths**

- Comprehensive coverage across multiple pathogens and parameter types
- Regular updates with new evidence
- Stable API endpoint performance

- **Challenges**

- Less intuitive than R packages (`{epiparameter}`, `{epireview}`)
- Data inconsistencies identified for studies reporting multiple estimates of the same parameter



---

## Ongoing Development



1. Refine and expand parameter categories
2. Standardize tools for extracting epidemiological parameters from scientific literature and outbreak data
3. Develop tools to facilitate integration of grEPI into analytical workflows
4. Establish quality assurance processes, enabling traceable community-driven contributions
5. Encourage sustained community engagement through contributor recognition and other incentives

---

# Interactive Session

---

# Q&A

---

# Thank you